Q-omics provides the consensus-scored HOXA7 profile across patient tissues and cancer cell-line models. HOXA7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, HOXA7 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, HOXA7 protein abundance shows 17,666 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UCEC, KIRC, and PDAC as cancer lineages where HOXA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXA7 survival associations across molecular data types. HOXA7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXA7 RNA expression–survival associations across cancer types. High HOXA7 expression shows unfavorable associations in UCEC, LGG, LAML, READ and CESC, but favorable associations in KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for HOXA7 RNA expression.
This table summarizes HOXA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HOXA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXA7 shows lower tumor expression in KIRC, BRCA, READ, LUAD and THCA and higher tumor expression in HNSC. The KIRC box plot shows higher HOXA7 RNA expression in normal versus tumor tissue (log2 FC = −1.600, t-test p < 0.001).
This table shows molecular features associated with HOXA7 in patient tissues and cancer cell lines. In patient samples, HOXA7 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Myeloma.
